[PET and malignant cerebral tumors].
Normal biodistribution of FDG includes intense physiologic uptake in the brain, which consumes glucose. The high background therefore makes it difficult to detect the foci taking up glucose, which correspond to malignant lesions. FDG PET is nevertheless clinically useful for detecting high-grade gliomas, cerebral lymphomas and, in some cases, unexpected brain metastases in whole-body PET examinations. As an adjunct to CT and MRI, FDG-PET can make stereotactic radiosurgery more precise in targeting primary or secondary brain cancers and can differentiate necrotic fibrosis from viable cancer tissue during follow-up in cases of abnormal or equivocal MRI results. When available, methionine-(11C) PET delineates low grade gliomas accurately. Several fluorine (18F)-labeled radiopharmaceuticals have been proposed in this setting, with FET and FDOPA apparently the most effective. Four original clinical cases illustrating performances of FET and FDOPA PET in this setting are presented.
Talbot
Jean-Noël
JN
Service de Médecine Nucléaire, AP-HP Hôpital Tenon, Université Pierre et Marie Curie, Paris. jean-noel.talbot@tnn.ap-hop-paris.fr
Kerrou
Khaldoun
K
Gault
Nicolas
N
Gutman
Fabrice
F
Grahek
Dany
D
Touboul
Emmanuel
E
Schlienger
Michel
M
Montravers
Françoise
F
D001932:Brain Neoplasms / Q000000981:diagnostic imaging*; D002794:Choline; D015224:Dideoxynucleosides; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives; D019788:Fluorodeoxyglucose F18; D005910:Glioma / Q000000981:diagnostic imaging; D006801:Humans; D008715:Methionine; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
D015224:Dideoxynucleosides; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine; D008715:Methionine; D002794:Choline; C002854:alovudine